Siren Fusion 2026: The Convergence of People, Technology and Ideas
4.3.2026 14:30:00 CET | Business Wire | Press Release
Siren today announced Siren Fusion 2026, its inaugural global summit convening senior investigators, national security leaders and AI innovators for a high-trust forum on the future of investigative intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304240853/en/
Siren Fusion 2026 is the convergence of people, technology and ideas, in Galway, Ireland. An invitation-only summit for global intelligence, national security and investigative leaders.
Taking place in Galway, Ireland, Fusion is the deliberate convergence of people, technology and ideas within a national security frame. Structured as an educational and strategic forum rather than a conventional conference, Fusion 2026 focuses on the issues that now define the intelligence and law enforcement agenda:
- Geopolitical instability
- AI-driven investigative transformation
- Cognitive warfare and influence operations
- Entity resolution and data integrity at scale
- The operational realities of modern investigations
Who Will Be in the Room?
By limiting attendance, Fusion prioritises executive-level engagement, direct access to Siren’s leadership and product teams, and substantive peer-to-peer collaboration that cannot occur in large-scale events.
A World-Class Line-Up of Global Leaders
The event brings together an exceptional list of leaders shaping the future of geopolitics, space, AI, and law enforcement including:
Geopolitical and Space
- Andrew Borene – Executive Director at Ocient National Security Solutions (ONSS) a former senior U.S. intelligence official and Marine Corps veteran who served as a Group Chief at the National Counterterrorism Center (NCSC)
- Major General (Retired) John Howard MNZM - former NZDF Chief of Defence Intelligence and former Deputy Director for Commonwealth Integration at the DIA
- Oleksandr V. Danylyuk – leading Ukrainian security expert and former senior advisor to the Ministry of Defense and Foreign Intelligence Service, specialising in Russian hybrid warfare and active measures. Oleksandr coordinates the Ukraine-NATO hybrid threat detection platform and co-delivers executive training on countering hybrid threats with King's College London.
- Vice Admiral (Retired) Mark Mellett, DSM – former Chief of Staff, Irish Defence Forces
- Sean Mitchell – Chairman and Chief Commercial Officer of Ubotica
Artificial Intelligence and Cognitive Warfare
- Lieutenant General (Retired) Michael Groen – former Director of the U.S. Department of Defense’s Joint Artificial Intelligence Centre
- Julian Stodd – 17-time published author and social learning strategist exploring how AI is reshaping leadership, culture, and organizational power in the digital age
- Dr. Renaud Delbru – Founder of Siren and Chief Scientific Officer
- Jeff Jonas – pioneering data scientist and CEO and Founder of Senzing
- Dr. Sae Schatz – expert in cognitive warfare and human performance
Law Enforcement Innovation
- Bob Griffin – Chairman of Siren, former CEO of i2 and COPLINK
- Kenrick Bagnall – Chief Cybersecurity Advisor and CISO, RCMP Cybercrime Investigations Instructor, Toronto Police Service C3, (Retired prevention and education)
- Tom M. Corvin – Alliances Director at Mark43
- Greg Lissy and Josh Hurwitz from Magnet Forensics - presenting the new Siren/Magnet API integration, bringing Magnet’s digital forensics data into the Siren platform
- Nico Dekens – widely known as Dutch_OsintGuy, is a globally recognised OSINT expert, certified instructor at SANS Institute, and Senior Vice President of Engineering and Chief Innovator at ShadowDragon, specialising in open-source intelligence and security analysis
Customer Perspective
- Jeremy Turner – VP, Threat Intelligence & Research, SecurityScorecard and long time user of Siren
John Randles, CEO of Siren, said of the event: “Fusion 2026 marks an important milestone for Siren. As investigative environments grow more complex, shaped by geopolitical instability, hybrid threats and AI, the need for strategic alignment across agencies and technologies has never been greater. This event is a measure to keep our community informed.”
Rachel Kavanagh, CMO of Siren, added: “Siren Fusion is intentionally different and reflects who we are as a company. We are creating a high-trust environment where leaders can engage in meaningful, strategic dialogue. We’re prioritising depth over scale, ensuring the right people are in the room.”
About Siren
Siren provides an AI-powered Investigative Intelligence Platform used by law enforcement, national security, cyber threat and fraud investigation teams worldwide. Siren enables organisations to unify complex data, apply advanced analytics and accelerate mission-critical investigations.
For more information, visit www.siren.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304240853/en/
Contacts
Media contact: media@siren.io
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom